Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Pharmaids Pharma
Quarter-by-quarter operating performance
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 5.81 | 4.73 | 5.24 | 4.71 | 4.77 | 6.66 | 8.61 | 5.43 |
| Expenses + | 0.69 | 8.60 | 1.61 | 1.02 | 2.45 | 11.39 | 8.14 | 7.65 | 7.60 | 8.67 | 12.03 | 13.93 | 7.94 |
| Operating Profit | -0.69 | -8.60 | -1.61 | -1.02 | -2.43 | -5.58 | -3.41 | -2.41 | -2.89 | -3.90 | -5.37 | -5.32 | -2.51 |
| OPM % | -12,150.00% | -96.04% | -72.09% | -45.99% | -61.36% | -81.76% | -80.63% | -61.79% | -46.22% | ||||
| Other Income + | 0.00 | 0.00 | 0.41 | -0.26 | 0.76 | 0.12 | -0.07 | 0.08 | 0.00 | 0.13 | 0.04 | 3.03 | -0.32 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.77 | 0.26 | 0.33 | 0.48 | 1.01 | 1.20 | 0.93 | 0.72 |
| Depreciation | 0.01 | 0.00 | 0.01 | 0.01 | 0.04 | 0.63 | 0.57 | 0.61 | 0.64 | 0.62 | 0.61 | 0.47 | 0.48 |
| Profit before tax | -0.70 | -8.60 | -1.21 | -1.29 | -1.73 | -6.86 | -4.31 | -3.27 | -4.01 | -5.40 | -7.14 | -3.69 | -4.03 |
| Tax % | 0.00% | -28.37% | 7.44% | -60.47% | -33.53% | -7.73% | -27.38% | -30.58% | -24.94% | -11.11% | -26.05% | -30.62% | -34.24% |
| Net Profit + | -0.71 | -6.16 | -1.30 | -0.50 | -1.15 | -6.33 | -3.12 | -2.27 | -3.01 | -4.80 | -5.27 | -2.57 | -2.65 |
| EPS in Rs | -0.54 | -2.87 | -0.61 | -0.23 | -0.54 | -1.57 | -0.76 | -0.55 | -0.55 | -1.12 | -1.39 | -0.71 | -0.70 |
Financials of Pharmaids Pharma
Annual income statement trend
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| Sales + | 4 | 0 | 15 | 19 | 25 |
| Expenses + | 4 | 10 | 27 | 32 | 43 |
| Operating Profit | 0 | -10 | -12 | -13 | -17 |
| OPM % | 3% | -82% | -66% | -67% | |
| Other Income + | 0 | 0 | 0 | 0 | 3 |
| Interest | 0 | 0 | 2 | 2 | 4 |
| Depreciation | 0 | 0 | 2 | 2 | 2 |
| Profit before tax | 0 | -10 | -16 | -17 | -20 |
| Tax % | 0% | -24% | -24% | -22% | |
| Net Profit + | 0 | -8 | -12 | -14 | -15 |
| EPS in Rs | 0.15 | -3.52 | -2.26 | -3.06 | -3.92 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
Financials of Pharmaids Pharma
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 10 | 21 | 35 | 35 | 35 |
| Reserves | -2 | 1 | 37 | 24 | 17 |
| Borrowings + | 0 | 0 | 9 | 39 | 20 |
| Other Liabilities + | 2 | 2 | 11 | 22 | 26 |
| Total Liabilities | 11 | 25 | 91 | 120 | 98 |
| Fixed Assets + | 0 | 0 | 63 | 77 | 55 |
| CWIP | 0 | 2 | 7 | 5 | 3 |
| Investments | 0 | 3 | 0 | 0 | 0 |
| Other Assets + | 11 | 19 | 21 | 39 | 41 |
| Total Assets | 11 | 25 | 91 | 120 | 98 |
Financials of Pharmaids Pharma
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Cash from Operating Activity + | -0 | -4 | -11 | -14 |
| Cash from Investing Activity + | 0 | -5 | -75 | -12 |
| Cash from Financing Activity + | 0 | 21 | 78 | 23 |
| Net Cash Flow | 0 | 12 | -8 | -3 |
| Free Cash Flow | -0 | -6 | -33 | -26 |
| CFO/OP | -200% | 41% | 86% | 109% |
Financials of Pharmaids Pharma
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 124 | 65 | 59 | |
| Inventory Days | 91 | 0 | 112 | 359 |
| Days Payable | 236 | 159 | 480 | |
| Cash Conversion Cycle | -21 | 17 | -63 | |
| Working Capital Days | -18 | -69 | -160 | |
| ROCE % | -64% | -26% | -17% |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…